Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > Antiviral compounds

<< Previous

Bullboard Posts

Next >>

Comment by forhandlarenon Feb 01, 2022 7:26am

162 Views

Post# 34383429

RE:Antiviral compounds

In the quartely update the company states:

"We are excited to report that we now have 20 compounds that entered testing for anti-COVID activity. These can take up to 6 weeks to complete and we expect results by the end of February 2022."

I think that the statement in December was premature and didn't take logistics into account.

End of February is when the company will get the results. Mid-March market communication would be reasonable.

A good result would be pretty easy to make sure it's picked by a major news channel to feed the hype. Let's see if they can manage this - the shareprice would spike!

<< Previous

Bullboard Posts

Next >>

Gold vs. bitcoin, where should you invest?